Dr. Fuad Fares

Dr. Fuad Fares |Clyto Access

University of Haifa, Israel

Editorial Board Member

Expertise: Human Genetic diseases, Cancer, Recombinant proteins, Biotechnology, Medicine


Dr. Fuad Fares completed his M.Sc and D.Sc studies at the Faculty of Medicine, Technion-Israel Institute of Technology, and postdoctoral studies at the Department of Molecular Biology and Pharmacology, School of Medicine, Washington University, St. Louis Missouri, USA. He developed the Molecular Genetic Laboratory at Carmel Medical Center, Haifa, Israel, and lead this laboratory last 24 years until October 2015. Now, he is the head of Molecular Genetic Laboratory at the Department of Human Biology, University of Haifa, Israel since 2004 and teaching genetics, genetic engineering and Endocrinology at the Faculty of Natural Sciences. He have published more than 90 manuscripts in reputed journals and serving as a member of the Israel Council for Higher Education last 15 years. Moreover, he is the founder and the inventor of PROLOR Biotech Company for designing long-acting recombinant proteins. PROLOR had an exit last year to OPKO Health Company in USA. He has developed a platform for developing long acting proteins, where he has found a cassette gene that ligated to the interested gene and then transfer it to eukaryotic cells for protein production. This way he developed long acting FSH in USA and this hormone (ELONVA) is marketed since 2010 by Merck Germany. Now he serve as CTO of OPKO Health, a board member of the NGT3 Biotechnology incubator based in Nazareth, Israel.


Related Conferences :